Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.

ABSTRACT:

Background

Non-alcoholic fatty liver disease (NAFLD) can lead to non-alcoholic steatohepatitis (NASH) and cirrhosis. Fibrosis predicts worse outcomes and mortality. New treatments targeting fibrosis are being investigated to reverse disease progression.

Aim

To review the new pipeline therapeutic agents targeting fibrosis in NASH patients, with particular focus on clinical trials in which reversing fibrosis and portal hypertension are the primary outcomes.

Methods

The literature was searched in PubMed between January 2000 and January 2016 using search terms non-alcoholic fatty liver disease and NASH, with filters of 'English language'. We focused on fibrosis improvement as the key outcome. We also searched the ClinicalTrials.gov for promising agents that target fibrosi

SUBMITTER: Noureddin M 

PROVIDER: S-EPMC5906100 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature